U.S. Markets open in 6 hrs 46 mins

Delcath Systems, Inc. (DCTH)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.16-0.08 (-32.26%)
At close: 4:00PM EDT
People also watch

Delcath Systems, Inc.

1633 Broadway
22nd Floor
New York, NY 10019
United States

IndustryDrug Delivery
Full Time Employees43

Key Executives

Dr. Jennifer K. Simpson Ph.D., M.S.N., C.R.N.P.Chief Exec. Officer, Pres and Director589.35kN/A49
Ms. Barbra C. Keck MBAChief Financial Officer306.03kN/A39
Mr. John PurpuraGlobal Head of Operations and Exec. VP385.38kN/A56
Mr. Robin WaggeSr. VP of Rubenstein AssociatesN/AN/AN/A
Mr. J. Chris HouchinsSr. VP of Clinical and Medical AffairsN/AN/A53
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company is developing melphalan hydrochloride for Injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. It offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.

Corporate Governance

Delcath Systems, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.